Gilead Faces Patent Challenge in France Over Sofosbuvir

The organization challenging Gilead is Médecins du Monde (MdM), an NGO that provides healthcare for vulnerable people around the world.

Doctors in France are challenging the patent of a new and highly expensive drug for hepatitis C in an attempt to bring down the price.

Sofosbuvir, costs $1,000 (£650) a pill for a 10-week course. The drug, made by the pharmaceutical multinational Gilead Sciences, is a cure for the viral infection that can lead to liver cirrhosis, cancer and death.

Even for affluent countries the bill is huge. In England, approximately 160,000 people are infected while globally, between 130 million and 150 million people are estimated to be infected, according to the World Health Organisation.

Read the complete news on The Guardian: http://bit.ly/1EVGZ7K